Why might vitiligo take more than one visit to confirm?
Because several other skin conditions can look similar on exam. Ruling those out is part of the process. It is not a sign your dermatologist doubts what you are seeing. Evidence Evidence Evidence
Why this item matters
- Sources cited, not yet graded
The BAD guideline lists conditions that can be mistaken for vitiligo. These include eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. For a patch at one site alone, especially a genital one, the guideline and the 2012 classification consensus both point to a biopsy. That biopsy checks for lichen sclerosus. NIAMS describes diagnosis as history and examination together. A Wood lamp and selected tests are used when relevant.
Check before moving on
- Depends on you
Neither source says how often vitiligo is first mistaken for one of these conditions. Neither says how many visits it usually takes to settle. The BAD guideline was written for UK care and read research through May 2019.
Questions for your dermatologist
What else did you consider before settling on vitiligo?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Would a biopsy or Wood-lamp exam help settle this, given where my patch is?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Why might a blood test come up at a skin visit?
Because vitiligo is linked to other autoimmune conditions. It is not because your dermatologist doubts the diagnosis. Thyroid testing is the one guidelines name specifically. Evidence Evidence Evidence
Why this item matters
- Sources cited, not yet graded
The BAD guideline calls autoimmunity a contributor to how vitiligo develops. It recommends thyroid function and antithyroid antibody screening. The AAD tells readers that vitiligo raises the risk of some other diseases, such as thyroid disease, and that a dermatologist can watch for them. NIAMS lists testing for associated autoimmune disease among the possible parts of evaluation.
Check before moving on
- Depends on you
A link between conditions is not a diagnosis. Having vitiligo does not mean another condition will develop. The BAD guideline sets no universal testing plan; which checks make sense for you is a clinical call.
Questions for your dermatologist
Given what you found so far, does thyroid or other autoimmune testing make sense for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How often would you repeat that test, if at all?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What can I bring so the visit has something to compare against?
A dated photo series, taken the same way every time. Add a plain note of when you first noticed each patch and what has changed since. Evidence Evidence
Why this item matters
- Sources cited, not yet graded
A patient-education photo-tracking method calls for a solid-colored background and the same artificial light and camera position each time, not sunlight. It calls for a straight-on shot held at three to five feet, the same body areas photographed each time, and a date on every photo. NIAMS separately frames evaluation around your own reported history of when patches appeared and what has changed.
Check before moving on
- Depends on you
This method was written for tracking change over time, not for diagnosis on its own. It names no study behind its exact distances or lighting choices. A photo series does not replace an in-person exam.
Questions for your dermatologist
Would a series like this actually help you, or is there a better way for me to track this?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What should I photograph before the next visit?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does what happens today decide my options for good?
No. Pattern and apparent activity shape what is realistic to discuss today, but the picture gets revisited. Some options, such as grafting, are kept specifically for vitiligo that has stopped changing. Evidence Evidence
Why this item matters
- Sources cited, not yet graded
The International Vitiligo Task Force names stable and active vitiligo as two states that change the care plan. Its assessment covers what the skin has done in the past six months. The BAD guideline’s recommendation R25 keeps cell grafting for vitiligo that is not changing and did not respond to other care. The same guideline says a doctor cannot always tell when vitiligo has truly stopped changing.
Check before moving on
- Depends on you
“Stable” is a clinical judgment revisited over time. It is not a verdict reached in one visit. Neither source promises a specific option will open up later, or says how long stability has to hold.
Questions for your dermatologist
Based on today, what would need to change before more options open up?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would you want to see, or not see, before the next review?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports patient-facing context that skin which has lost its color can burn readily and that shade, clothing and labeled sunscreen use are broad protection options. It also supports that for some people a skin injury triggers new spots or patches, and it names cuts, scrapes and burns. The wound a tattoo makes can lead to the Koebner phenomenon, with new spots appearing about 10 to 14 days later. It supports that a tattoo added for pigment may not blend with natural skin color, that its color can eventually bleed, and that the vitiligo underneath can spread over time. It supports the page telling readers to avoid tanning, indoors and outdoors, because tanning increases the contrast between natural skin color and the light spots and patches. That is what it says makes vitiligo more noticeable. It supports that tanning beds, sun lamps and other indoor tanning devices are not safe alternatives to the sun. Like the sun, they can burn skin that has lost pigment and worsen vitiligo. It supports that a bad sunburn can worsen vitiligo, and that on a lighter skin tone untanned skin often makes the spots and patches less noticeable. It supports that self-tanners and skin dyes tend to last 3 to 5 days, against one day for makeup. It names dihydroxyacetone as the ingredient to look for, and says natural-looking results take practice. It supports that vitiligo increases the risk of some other diseases such as thyroid disease, and that a dermatologist can monitor for them.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish treatment efficacy. It does not establish a personalized sun plan, a product ranking or a treatment-day instruction. It gives no frequency for injury-related patches and no way to tell in advance who they happen to. It gives no measure of how much tanning changes contrast, no threshold for a bad sunburn, and no way to tell whether one person’s vitiligo will worsen. It compares no tanning device with prescribed narrowband UVB and establishes nothing about medical phototherapy. It names no product or brand for camouflage, self-tanner or skin dye.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- MyVitiligoTeamPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a solid-colored background for a comparable photo series. Black, green, or dark blue are named as ones that help skin stand out. Supports using the same artificial light in the same position each time, rather than sunlight. Supports holding the camera straight rather than tilted. Supports a distance of about 3 to 5 feet, held the same every time. Supports photographing a fixed list of body areas the same way every time. Supports using a ruler for scale and tagging each photo with its date.
What it does not support
Written and reviewed for tracking vitiligo, a different condition, not for psoriasis. Only the general camera technique - background, lighting, angle, distance, and framing - is used here; nothing about vitiligo itself is carried over. Does not establish that photo tracking changes any psoriasis outcome.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Pigment Cell & Melanoma Research (Ezzedine K, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports separating segmental vitiligo from nonsegmental forms and recognizing mixed and initially unclassified presentations. Classification is a clinical and longitudinal judgment. Its section on the Koebner phenomenon supports defining that phenomenon as patches developing at sites of previously unaffected skin that was specifically injured. It endorses the Vitiligo European Task Force classification of that phenomenon into history-based, clinical-observation-based and experimentally induced forms. Its section on mucosal vitiligo defines that term as the oral or genital mucosae. Where the patches are at one site alone, and especially a genital one, that section says a differential diagnosis of lichen sclerosus should be addressed by biopsy. It records that genital lichen sclerosus and vitiligo have been reported together.
What it does not support
It does not support self-classification from symmetry, one patch or a photograph, and it does not predict an individual response. On the Koebner phenomenon it records a general impression that the phenomenon and disease stability are related, then states that objective data are lacking. It also says scientific evidence is lacking for attributing vitiligo to daily friction from washing, dressing, personal care, sports, occupational activity or pressure from clothing. On lichen sclerosus it cites one reference from 2000 and calls a link a possibility, not a finding. It counts nothing and gives no rate.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.